Canadian study uncovers mechanism behind dangerous blood clots linked to heparin
Researchers at McMaster University have identified how a common blood thinner, heparin, can trigger life-threatening blood clots in some patients.
Key Takeaways
AIA multidisciplinary research team at McMaster University in Canada has identified the mechanism that may cause some patients to develop dangerous blood clots after receiving heparin, a widely used blood thinner.
The study explains how a natural blood protein can become a target for harmful antibodies, leading to an immune condition known as heparin-induced thrombocytopenia (HIT).
Researchers focused on platelet factor 4 (PF4), a natural protein involved in blood clotting. In some patients treated with heparin, the structure of this protein can change, making it a target for antibodies that trigger an immune response. This can result in the formation of dangerous clots, which may cause stroke, heart attack, limb loss, or even be life-threatening if not diagnosed and treated promptly.
Using nuclear magnetic resonance (NMR) spectroscopy, the team identified what they described as a "molecular switch" within the PF4 protein that controls its shape. They demonstrated that keeping the protein in its closed state significantly reduces its ability to provoke an immune response, suggesting this mechanism could be used to develop new diagnostic or therapeutic approaches.
The findings are the result of collaboration between researchers in chemistry, structural biology, medicine, and transfusion medicine, led by Giuseppe Melacini and Ishac Nazy, along with postdoctoral researcher Qiulin Ma.
Melacini said that identifying the structural change that turns PF4 into a disease-causing antigen offers a new approach for detecting or preventing dangerous immune reactions.
Nazy noted that combining molecular imaging techniques with clinical expertise helped the team understand why the protein becomes a target for harmful antibodies.
The researchers believe their findings could pave the way for more accurate diagnostic tests for early detection of disease-causing antibodies, enabling faster intervention and reducing complications.
The approach used in the study may also serve as a model for investigating other diseases linked to subtle structural changes in proteins that affect their function.